Assessing the TP53 marker type in patients treated with or without neoadjuvant chemotherapy for resectable colorectal liver metastases: A p53 Research Group study

European Journal of Surgical Oncology

Volumn 41, Issue 5, 2015, Pages 683-689

  Pilat, N ^a   Grunberger T ^a   Langle F ^a   Mittlbock M ^a   Perisanidis, B ^a   Kappel, S ^a   Wolf, B ^a   Starlinger, P ^a   Kuhrer I ^a   Muhlbacher F ^a   Kandioler, D ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Biomarker tp53; Colon cancer liver metastases; Differentiation of prognostic and predictive value

Indexed keywords

FLUOROURACIL; OXALIPLATIN; PROTEIN P53; ANTINEOPLASTIC AGENT; GENETIC MARKER; PLATINUM COMPLEX;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL LIVER METASTASIS; DIAGNOSTIC KIT; DISEASE SEVERITY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; ADJUVANT THERAPY; CASE CONTROL STUDY; COLORECTAL TUMOR; GENETIC MARKER; GENETICS; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SECONDARY; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; GENES, P53; GENETIC MARKERS; GENOTYPE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE;

EID: 84931345403     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2015.02.003     Document Type: Article

References (31)

1. Duffy MJ. Predictive markers in breast and other cancers: a review. Clin Chem 2005;51:494-503.
2. McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 2006;100:229-35.
3. Meek DW. Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 2009;9:714-23.
4. Hainaut P, Wiman KG. 25 years of p53 research. The Netherlands: Springer; 2005.
5. Kern SE, Winter JM. Elegance, silence and nonsense in the mutations literature for solid tumors. Cancer Biol Ther 2006;5:349-59.
6. Hoff PM. Is there a role for routine p53 testing in colorectal cancer? J Clin Oncol 2005;23:7395-6.
7. Duffy MJ, van Dalen A, Haglund C, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007;43:1348-60.
8. Kandioler D, Kappel S, Wolf B. Designing p53 trials: a surgical oncologists view. In: Hainaut P, Olivier M, Wiman KG, editors. p53 in the clinics. Springer Science + Business Media; 2013;, p. 289-303.
9. Russo A, Bazan V, Iacopetta B, et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 2005;23:7518-28.
10. Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005;92:434-44.
11. De Bruijn MT, Raats DA, Tol J, et al. Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer. Anticancer Res 2011;31:1379-85.
12. Mandrekar SJ, Sargent DJ. Predictive biomarker validation in practice: lessons from real trials. Clin Trials 2010;7:567-73.
13. Tezak Z, Kondratovich M, Mansfield E. US FDA and personalized medicine: in vitro diagnostic regulatory perspective. Pers Med 2010;7:517-30.
14. den Dunnen JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 2000;15:7-12.
15. Kato S, Han SY, Liu W, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 2003;100:8424-9.
16. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007;28:622-9.
17. Italiano A. Prognostic or predictive? It's time to get back to definitions!. J Clin Oncol 2011;29:4718. [author reply - 9].
18. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 2009;27:4027-34.
19. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005;23:2020-7.
20. Ma X, Rousseau V, Sun H, et al. Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer. Mol Oncol 2014;8:555-64.
21. Akiyama J, Alexandre L, Baruah A, et al. Strategy for prevention of cancers of the esophagus. Ann N Y Acad Sci 2014;1325:108-26.
22. Petersen S, Thames HD, Nieder C, Petersen C, Baumann M. The results of colorectal cancer treatment by p53 status: treatment-specific overview. Dis Colon Rectum 2001;44:322-33. [discussion 33-34].
23. Simon RM. Guidelines for the design of clinical studies for the development and validation of therapeutically relevant biomarkers and biomarker-based classification systems. In: Gasparini G, Hayes D, editors. Biomarkers in breast cancer. Totowa: Humana Press; 2006;, p. 3-15.
24. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001;1:233-40.
25. Lane DP. Exploiting the p53 pathway for the diagnosis and therapy of human cancer. Cold Spring Harb Symp Quant Biol 2005;70:489-97.
26. Agell L, Hernandez S, de Muga S, et al. KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations. Mod Pathol Off J U S Can Acad Pathol Inc 2008;21:1470-8.
27. Edlund K, Larsson O, Ameur A, et al. Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors. Proc Natl Acad Sci U S A 2012;109:9551-6.
28. Kandioler D, Zwrtek R, Ludwig C, et al. TP53 genotype but not p53 immunohistochemical result predicts response to preoperative shortterm radiotherapy in rectal cancer. Ann Surg 2002;235:493-8.
29. Kandioler D, Stamatis G, Eberhardt W, et al. Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer. J Thorac Cardiovasc Surg 2008;135:1036-41.
30. Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000;6:50-6.
31. Kandioler D, Schoppmann SF, Zwrtek R, et al. The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study. J Thorac Cardiovasc Surg 2014. http://dx.doi.org/10.1016/j.jtcvs.2014.06.079.